A. Sipos

发表

Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors.

A. Ullrich, L. Őrfi, C. Szántai-Kis, 2014, Current medicinal chemistry.

Novel, selective CDK9 inhibitors for the treatment of HIV infection.

Á. Gyuris, J. Minárovits, L. Őrfi, 2011, Current medicinal chemistry.

Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.

G. Kéri, L. Őrfi, J. Pató, 2013, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.

G. Kéri, S. Szathmary, Á. Gyuris, 2014, Journal of medicinal chemistry.

Targeted drug combination therapy design based on driver genes

G. Kéri, L. Őrfi, D. Erős, 2019, Oncotarget.

Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.

L. Őrfi, C. Szántai-Kis, Z. Nemes, 2019, European journal of medicinal chemistry.

Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.

L. Őrfi, C. Szántai-Kis, Z. Horváth, 2018, Bioorganic & medicinal chemistry letters.

Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.

G. Kéri, L. Őrfi, C. Szántai-Kis, 2016, European journal of medicinal chemistry.

Lead selection and characterization of antitubercular compounds using the Nested Chemical Library.

G. Kéri, S. Cole, V. Nagaraja, 2015, Tuberculosis.

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.

É. Remenár, R. Dóczi, I. Peták, 2022, JCO precision oncology.

[Pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction].

G. Kéri, L. Őrfi, B. Hegymegi-Barakonyi, 2014, Acta pharmaceutica Hungarica.